Calithera Biosciences, Inc.
Calithera Biosciences, Inc. (CALA) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
cala · stock forecast · 10 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 10 Wall Street analysts in the past 3 months
Buy
10 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$2.00
Consensus
$2.00
+666566.6% upside
Low
$2.00
Median: $2 · Last Close: $0.00
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $0.00 | ↑ 0.00% |
1-day model range: $0–$0. Peak: $0 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CALA · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2022-11-15 | SVB Leerink | Downgrade ↓ | Outperform→Market Perform |
| 2022-11-15 | Ladenburg Thalmann | Downgrade ↓ | Buy→Neutral |
| 2022-08-29 | HC Wainwright & Co. | Upgrade ↑ | Neutral→Buy |
| 2022-08-16 | SVB Leerink | Maintains | Outperform→Outperform |
| 2022-05-11 | Wells Fargo | Maintains | Equal Weight→Equal Weight |
| 2022-04-04 | SVB Leerink | Maintains | Outperform→Outperform |
| 2022-01-31 | Ladenburg Thalmann | Maintains | Buy→Buy |
| 2022-01-20 | SVB Leerink | Upgrade ↑ | Market Perform→Outperform |
| 2021-11-08 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2021-11-05 | William Blair | Downgrade ↓ | Outperform→Market Perform |
Wall Street analysts have recently issued updated ratings on Calithera Biosciences, Inc. (CALA) stock. Of the recent 29 rating actions, 4 were upgrades and 5 were downgrades. 10 analysts currently cover CALA.
Analyst Recommendation Trends
CALA analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
Revenue Next Year
$5M
EPS This Year
$-8.62
EPS Next Year
$-5.00
↓ 42.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast CALA EPS of $-8.62 for the current fiscal year, based on estimates from 1 analysts. The CALA revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CALA stock forecast is supported by two independent data sources: analyst consensus ratings from 10 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CALA price target is $2.00 (+666566.6% upside), with an analyst consensus of Buy.
The CALA short-term stock prediction for tomorrow is $0.00 (+0.00%).
Calithera Biosciences, Inc. trades on OTC under the ticker CALA. The CALA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 60% of covering analysts.
Frequently asked questions
CALA forecast · 8 questionsAccording to 10 Wall Street analysts, the average 12-month CALA price target is $2.00, with a high forecast of $2.00 and a low of $2.00. The median price target is shown in the chart above when available. This implies +666566.6% potential upside from the current price of $0.00.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.